The Kura Oncology Inc (KURA) Issues Earnings Results

The Kura Oncology Inc (KURA) Issues  Earnings Results

Kura Oncology (NASDAQ KURA) opened at 8.30 on Monday. The firm’s market capitalization is $163.24 million. The firm has a 50 day moving average of $9.58 and a 200 day moving average of $7.62. Kura Oncology has a one year low of $2.50 and a one year high of $12.10.

Kura Oncology Inc (NASDAQ:KURA) announced its earnings results on Monday. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.05, Bloomberg Earnings reports.

A number of equities analysts recently issued reports on the stock. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Kura Oncology in a research report on Thursday, February 9th. Cann raised their price objective on shares of Kura Oncology to $18.00 and gave the company an “outperform” rating in a research report on Wednesday, February 8th. Finally, Zacks Investment Research lowered shares of Kura Oncology from a “buy” rating to a “sell” rating in a research report on Saturday, February 11th.

A number of large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in Kura Oncology during the first quarter valued at approximately $533,000. Oppenheimer & Co. Inc. boosted its stake in Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock valued at $110,000 after buying an additional 1,600 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Kura Oncology by 158.8% in the first quarter. Renaissance Technologies LLC now owns 79,200 shares of the company’s stock valued at $697,000 after buying an additional 48,600 shares in the last quarter. Morgan Stanley boosted its stake in Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after buying an additional 274,166 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Kura Oncology by 0.9% in the first quarter. Geode Capital Management LLC now owns 49,682 shares of the company’s stock valued at $437,000 after buying an additional 426 shares in the last quarter. 45.73% of the stock is owned by institutional investors and hedge funds.

Kura Oncology Company Profile Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:KURA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Kura Oncology Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kura Oncology Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment